En termes de travail: terminologie comparée grec-français à partir d’un corpus de l’administration publique

This article presents a comparative study of French and Greek administrative language, as it is used by public administration institutions in their internal communication as well as in their external communi- cation with the citizens. In the present study, we employ a corpus-based contrastive approach, by using bilingual comparable corpora in the subject field of “employment”. First, we present our method concerning the compilation of the comparable corpora and the digital tools used for their processing analysis; and then, we proceed with the analysis of the textual data from a contrastive perspective. We aim to highlight the morphosyntactic, semantic, and pragmatic aspects that characterize the terms studied across the two languages.This article presents a comparative study of French and Greek administrative language, as it is used by public administration institutions in their internal communication as well as in their external communi- cation with the citizens. In the present study, we employ a corpus-based contrastive approach, by using bilingual comparable corpora in the subject field of “employment”. First, we present our method concerning the compilation of the comparable corpora and the digital tools used for their processing analysis; and then, we proceed with the analysis of the textual data from a contrastive perspective. We aim to highlight the morphosyntactic, semantic, and pragmatic aspects that characterize the terms studied across the two languages. &nbsp

HELLAS-ALIENS. The invasive alien species of Greece: time trends, origin and pathways

The current paper presents the first effort to organize a comprehensive review of the Invasive Alien Species (IAS) of Greece. For this purpose, a database was developed with fields of information on the taxonomy, origin, ecology and pathways of introduction of terrestrial, freshwater and marine species. Our database includes a) taxa in the Union’s list that are present in Greece, b) taxa already present in Greece and considered to be invasive, and c) taxa highly likely to enter Greece in the next 10 years and become invasive. The Database served as the starting point for the compilation of the National List of Alien Invasive Species (HELLAS-ALIENS) in compliance with the EU Regulation 1143/2014. Overall, the HELLAS-ALIENS comprises 126 species, i.e. 32 terrestrial and freshwater plant species, 14 terrestrial invertebrates, 28 terrestrial vertebrates, 30 freshwater fishes and invertebrates and 22 marine species. Terrestrial invertebrates, birds and mammals are mainly of Asiatic origin. Most of the terrestrial plants have their native geographical distribution in the Americas (North and South). Most of the freshwater invertebrates and fishes are of North American origin, while the majority of the marine species are of Indo-Pacific origin. The first records of IAS concern terrestrial plant species, and date back to the 19th century, while those in freshwater and marine ecosystems seem to have been systematically recorded some decades later. Regarding the pathways of introduction, most of the taxa arrived in Greece or are expected to arrive through escape from confinement and unaided. The majority of the terrestrial, freshwater and marine species have been evaluated as of High-risk for the indigenous biodiversity and only 3% of the species listed have been evaluated of Low-risk. Our results provide an important baseline for management and action plans, as required by the priorities set by the European Union through the Biodiversity Strategy for 2030

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

Simple Summary There is limited information on the safety and efficacy of approved SARS-CoV-2 vaccines in cancer patients, as they were excluded from registration vaccine trials. We investigated the humoral immunity post SARS-CoV-2 vaccination in cancer patients compared to healthy volunteers. In this prospective cohort study, the seropositivity rate after two doses of vaccine was high in cancer patients despite active antineoplastic treatment, but their antibody titers were significantly lower than in healthy control subjects. Factors affecting immunogenicity in cancer patients, included older age, poor PS, active treatment, certain cancer types, i.e., pancreatic cancer and SCLC, male gender, and, interestingly, smoking status. Our results suggest that, given the lower immunogenicity, adjustments in vaccination strategies for more vulnerable subgroups of cancer patients may be required. Monitoring of antibody responses and elucidation of the clinical factors that influence immunity could guide future vaccination policies. Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited. This observational, prospective cohort study investigated the humoral immune response to SARS-CoV-2 vaccination in 232 cancer patients from 12 HeCOG-affiliated oncology departments compared to 100 healthcare volunteers without known active cancer. The seropositivity rate was measured 2-4 weeks after two vaccine doses, by evaluating neutralising antibodies against the SARS-CoV-2 spike protein using a commercially available immunoassay. Seropositivity was defined as >= 33.8 Binding-Antibody-Units (BAU)/mL. A total of 189 patients and 99 controls were eligible for this analysis. Among patients, 171 (90.5%) were seropositive after two vaccine doses, compared to 98% of controls (p = 0.015). Most seronegative patients were males (66.7%), >70-years-old (55.5%), with comorbidities (61.1%), and on active treatment (88.9%). The median antibody titers among patients were significantly lower than those of the controls (523 vs. 2050 BAU/mL; p < 0.001). The rate of protective titers was 54.5% in patients vs. 97% in controls (p < 0.001). Seropositivity rates and IgG titers in controls did not differ for any studied factor. In cancer patients, higher antibody titers were observed in never-smokers (p = 0.006), women (p = 0.022), <50-year-olds (p = 0.004), PS 0 (p = 0.029), and in breast or ovarian vs. other cancers. Adverse events were comparable to registration trials. In this cohort study, although the seropositivity rate after two vaccine doses in cancer patients seemed satisfactory, their antibody titers were significantly lower than in controls. Monitoring of responses and further elucidation of the clinical factors that affect immunity could guide adaptations of vaccine strategies for vulnerable subgroups

Deliverable 6.2: Trials and experimentation (cycle 2)

This deliverable presents the second cycle of trials and experimentation activities executed over 5GENESIS facilities. The document is the continuation of deliverable D6.1, in the sense that it captures tests carried out over the evolved infrastructures hosting 5GENESIS facilities following the methodology defined in D6.1. In this document 8 main KPIs and 4 application specific validation trials achieved, under 123 experiments that performed in total. The tests focus more on i) the evolved 5G infrastructure deployments that includes radio and core elements in non-standalone (NSA) deployment configurations based on commercial and open implementations, and ii) the use of Open 5GENESIS Suite for the execution of the tests.5GENESI

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

Our aim was to determine the prevalence, prognostic and predictive role of germline pathogenic/likely pathogenic variants (P/LPVs) in cancer predisposing genes in patients with pancreatic ductal adenocarcinoma (PDAC). Germline testing of 62 cancer susceptibility genes was performed on unselected patients diagnosed from 02/2003 to 01/2020 with PDAC, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated Centers. The main endpoints were prevalence of P/LPVs and overall survival (OS). P/LPVs in PDAC-associated and homologous recombination repair (HRR) genes were identified in 22 (4.0%) and 42 (7.7%) of 549 patients, respectively. P/LPVs were identified in 16 genes, including ATM (11, 2.0%) and BRCA2 (6, 1.1%), while 19 patients (3.5%) were heterozygotes for MUTYH P/LPVs and 9 (1.6%) carried the low-risk allele, CHEK2 p.(Ile157Thr). Patients carrying P/LPVs had improved OS compared to non-carriers (22.6 vs. 13.9 months, p = 0.006). In multivariate analysis, there was a trend for improved OS in P/LPV carriers (p = 0.063). The interaction term between platinum exposure and mutational status of HRR genes was not significant (p-value = 0.35). A significant proportion of patients with PDAC carries clinically relevant germline P/LPVs, irrespectively of age, family history or disease stage. The predictive role of these P/LPVs has yet to be defined. ClinicalTrials.gov Identifier: NCT03982446